Introduction {#s01}
============

Synaptic transmission mediates rapid information transfer in neuronal circuits. The dynamic rearrangement of synaptic structure and efficacy in response to changes in neuronal activity or trophic support is critical for information processing, learning, and memory ([@bib1]; [@bib51]; [@bib66]). Early studies indicate that changes in presynaptic and postsynaptic architecture and efficacy can be controlled by ubiquitination ([@bib28]; [@bib8]), a dynamic and reversible posttranslational protein modification, which can regulate protein expression, activity, or localization. Ubiquitin-mediated signaling is regarded as a critical mechanism controlling synaptic plasticity, and its failure has been linked to numerous neurological, neurodegenerative, and psychiatric diseases ([@bib69]; [@bib38]; [@bib46]; [@bib27]).

The transfer of ubiquitin onto a substrate requires an enzymatic cascade including ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3). The most abundantly diverse components of this system are E3 ligases, which comprise hundreds of genes in mammals and are grouped into the HECT domain and RING finger families. The largest class of RING ligases are Cullin-RING finger ligases, which are assembled from a Cullin scaffold that associates with the RING finger protein to recruit an E2 enzyme and an adaptor for substrate recruitment ([@bib56]; [@bib13]; [@bib45]).

Vertebrates have seven Cullins. The two Cul4 paralogs (A/B) are mostly identical except for the long N terminus and nuclear localization signal (NLS) of Cul4B. Cul4 ligase complexes mediate cell cycle regulation, embryogenesis, DNA replication, DNA damage and repair, and epigenetic control of gene expression ([@bib13]; [@bib25]). Mutations in human Cul4B have been linked to intellectual disability and epilepsy ([@bib70]; [@bib50]; [@bib43]). Consistently, conditional Cul4B KOs show spatial learning deficits, altered dendritic properties in the hippocampus, and an increased susceptibility to stress-induced seizures ([@bib6]).

Cul4A/B likely use Damaged DNA binding protein-1 (DDB1) as a unique adaptor to target substrates ([@bib65]; [@bib34]). Proteomic studies suggest that DDB1 links human Cul4 with \>60 different potential substrate receptors termed DDB1-Cul4--associated factors (DCAFs). Of these, 52 contain a WD40 domain ([@bib2]; [@bib26]; [@bib30]; [@bib35]). One of these, human DCAF12, was identified as a DDB1 binding protein and component of Cul4A/B complexes ([@bib2]; [@bib35]; [@bib52]). DCAF12 expression is altered in various human cancer cells ([@bib61]; [@bib39]), and it is required for the apoptotic elimination of supernumerary cells during *Drosophila melanogaster* metamorphosis ([@bib32]). However, DCAF12's role in neural and synaptic function has remained elusive.

Here, we show that presynaptic DCAF12 is required for evoked neurotransmitter release and homeostatic synaptic potentiation. Postsynaptic DCAF12 is required to down-regulate the synaptic expression of the glutamate receptor subunits GluRIIA, GluRIIC, and GluRIID. Further analysis validated a critical role of DCAF12 for Cul4-mediated protein ubiquitination and revealed that nuclear DCAF12 and Cul4 cooperate to indirectly down-regulate synaptic GluRIIA levels.

Results {#s02}
=======

Identification of lethal mutations in DCAF12 {#s03}
--------------------------------------------

Ethyl methanesulfonate--induced recessive lethal alleles in *Drosophila* DCAF12 were identified through a genetic screen for genes that facilitate synaptic function ([@bib23]). Mapping of the two alleles *B332* and *B417* identified DNA polymorphisms in the *Drosophila* orthologue of human DCAF12 (WDR40A and TCC52; [Fig. 1, A--C](#fig1){ref-type="fig"}). The *B332* allele causes an amino acid substitution (C138Y) in the first WD40 repeat, while *B417* substitutes the stop codon and adds 12 amino acids ([Fig. 1 C](#fig1){ref-type="fig"}). We also generated the CRISPR/CAS9-induced deletion Δ*51* (2,008 bp), which removes the entire coding region ([Fig. 1 B](#fig1){ref-type="fig"}).

![**Genetic and molecular analysis of DCAF12. (A)** Deficiency (Df) mapping of alleles *B332* and *B417*. Closed and open bars indicate deficiencies and genes, respectively. **(B and C)** Structure of the *dcaf12* gene and DCAF12 protein. **(D)** 3-d-old control (*w^1118^*) and *Δ51* mutant pupae. **(E and F)** Traces (E) and quantification (F) of crawling from control and *Δ51* third-instar larvae (means ± SEM; *n* ≥ 6; \*\*, P \< 0.004; two-tailed unpaired *t* test).](JCB_201805099_Fig1){#fig1}

The homozygous alleles *B332* and *Δ51* arrest development during late larval-to-pupal stages. In contrast, homozygous *B417* animals die during embryogenesis. Locomotion of homozygous *B332* and *Δ51* third-instar larvae is significantly impaired ([Fig. 1, E and F](#fig1){ref-type="fig"}; and Fig. S2 A) and pupation is delayed by ∼3--4 d. Mutant pupae lack discernible abdominal contractions and exhibit necrotic tissues ([Fig. 1 D](#fig1){ref-type="fig"}).

DCAF12 protein is expressed in neurons, glia, and muscles of *Drosophila* larvae {#s04}
--------------------------------------------------------------------------------

To determine the subcellular localization of DCAF12, we generated two polyclonal antibodies (GP11 and GP12). The GP12 specifically detects an ∼55-kD protein band on Western blots of WT larval brain extracts but not *dcaf12^Δ51^* deletion mutants (Fig. S1 A).

In fly larvae, DCAF12 is expressed in neurons, glia, and muscles ([Figs. 2](#fig2){ref-type="fig"} and [3 A](#fig3){ref-type="fig"}). In glia and neurons, DCAF12 is found in both the nucleus and cytoplasm ([Fig. 2, C and O](#fig2){ref-type="fig"}; and Fig. S1, D--I). DCAF12 expression is particularly high in axons of photoreceptors and segmental nerves exiting the ventral nerve cord ([Fig. 2, A and B](#fig2){ref-type="fig"}). In muscles, DCAF12 is primarily nuclear and prominently enriched in a few large foci ([Fig. 3, A, B, D, and E](#fig3){ref-type="fig"}). DCAF12's nuclear localization depends on its predicted NLS because overexpressed DCAF12 lacking parts of the NLS (ΔNLS; [Fig. 1 C](#fig1){ref-type="fig"}) is exclusively cytoplasmic (Fig. S1, G and H).

![**Subcellular localization of neuronal DCAF12. (A and B)** Larval ventral nerve cord and eye disc stained for DCAF12 (GP11). **(C)** Neuronal somata stained for DCAF12 (GP12) and Lamin-C marking the nuclear envelope. **(D)** Larval NMJs stained for DCAF12 (GP11) and HRP marking the neuronal membrane. **(E and F)** Axons of NMJ (E) stained for DCAF12 and HRP and plot (F) of a single line scan (gray line in E) of DCAF12 and HRP fluorescence (*n* = 1). **(G and H)** Axons of NMJ stained for DCAF12 and Futsch (G) and plot (H) of a single line scan (gray line in G) of DCAF12 and Futsch fluorescence (*n* = 1). **(I and J)** Synaptic boutons stained for DCAF12 and postsynaptic DLG (I) or DCAF12 and HRP (J). **(K)** Frequency distribution of DCAF12 fluorescence in synaptic boutons of control (*n* = 118; *n* = 3) and *Δ51* (*n* = 72; *n* = 3). **(L)** Synaptic boutons stained for DCAF12 and Brp (AZ). **(M--O)** Quantification of anti-DCAF12 fluorescence intensity (FI; means ± SEM; *n* ≥ 8; \*\*\*, P \< 0.0002; two-tailed unpaired *t* test). Scale bars, 50 µm (A and B), 20 µm (D), 10 µm (E, I, and J), 5 µm (C and G), and 2.5 µm (L).](JCB_201805099_Fig2){#fig2}

![**Nuclear DCAF12 interacts with Cul4. (A)** Muscle nuclei stained for DCAF12 (GP11) and Lamin-C. **(B and C)** Muscle nuclei stained for DCAF12 (B and C) and γ-tubulin (B), Cul4 (B), or Lamin-C (C). **(D--G)** Amount of DCAF12 foci (D and F) and levels (E and G) in muscle nuclei (*n* ≥ 35; \[D and E\], *n* ≥ 9; \[F and G\], *n* ≥ 3). **(H)** Muscle nuclei stained for coexpressed DCAF12 and flagCul4. **(I)** Western blot of GFP pull-downs (PD) probed with anti-V5 from S2 cell extracts expressing V5-DCAF12, GFP and V5-DCAF12, or V5-DCAF12 and GFP-DDB1. GAPDH was used as a loading control. **(J)** Muscle nuclei stained for mycDDB1 and DCAF12. **(K--N)** Muscle surface area (MSA \[K and N\]), nuclear area (L), and normalized number (M) of nuclei (*n* ≥ 11). **(O)** Muscles stained for DCAF12. **(P--R)** Reduced Cul4 levels suppress DCAF12 OE effects on MSA (P), normalized bouton number (Q), and size (R) of nuclei (*n* ≥ 6). Scale bars, 20 µm (A and O), 10 µm (H and J), and 5 µm (B and C). Graphs display means ± SEM. Statistical analysis used two-tailed unpaired *t* test (E and K--N), Mann--Whitney test (D), or one-way ANOVA (F, G, and P--R); \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JCB_201805099_Fig3){#fig3}

At larval neuromuscular junctions (NMJs), DCAF12 is essentially presynaptic ([Fig. 2, D and I](#fig2){ref-type="fig"}), where it is strongly expressed in axons and to a variable degree in synaptic boutons ([Fig. 2, D--F, J, K, M, and N](#fig2){ref-type="fig"}). Small amounts are also detectable in glial processes of NMJs (Fig. S1, I and J). In synaptic boutons, presynaptic DCAF12 does not overlap with BRP-positive active zones (AZs; [Fig. 2 L](#fig2){ref-type="fig"}). In axons, DCAF12 is associated with the plasma membrane marked by HRP and shows little overlap with Futsch-positive microtubules ([Fig. 2, E--H](#fig2){ref-type="fig"}). The residual immunofluorescence detected in axons, boutons, and nuclei of *Δ51* deletion mutants is due to an unspecific cross-reactivity of the antibodies ([Fig. 2, M--O](#fig2){ref-type="fig"}).

DCAF12 forms a nuclear complex with Cul4 {#s05}
----------------------------------------

The focal enrichment of DCAF12 in larval muscle nuclei ([Fig. 3, A and B](#fig3){ref-type="fig"}) was reminiscent of the centrosomal localization of human DCAF12 in cancer cells ([@bib39]). However, in fly muscle nuclei, DCAF12-positive foci did not colocalize with the centrosomal marker γ-tubulin ([Fig. 3 B](#fig3){ref-type="fig"}); the Cajal body marker Coilin; DNA; or the nuclear proteins SMT3, Importin13, Lamin-C, Lola, and pMAD (Fig. S1 K).

Human DCAF12 has been identified as a component of Cul4 ligase complexes through its interactions with DDB1 ([@bib2]; [@bib35]). Consistently, GFP pull-down assays of EGFP-tagged DDB1 from *Drosophila* S2 cells extracts copurified V5-tagged DCAF12 ([Fig. 3 I](#fig3){ref-type="fig"}). Immunoprecipitation of flag-Cul4 from adult fly brain extracts copurified a modified ∼72-kD DCAF12-positive band instead of the normal-sized 55-kD band (Fig. S1 B). Overexpression (OE) of normal and flag-tagged DCAF12 in adult fly neurons indicated that the ∼72-kD band likely represents DCAF12 (Fig. S1 C).

Next, we tested whether DCAF12 colocalizes with fly Cul4. Like human Cul4B ([@bib76]), fly Cul4 is mostly nuclear and enriched in a few foci that colocalized with DCAF12 ([Fig. 3 B](#fig3){ref-type="fig"}). Deletion of DCAF12 by the null allele *Δ51* abolished nuclear Cul4-positive foci ([Fig. 3 B](#fig3){ref-type="fig"}). In contrast, RNAi-mediated knockdown (KD) of Cul4 abolished nuclear DCAF12 foci without affecting nuclear DCAF12 levels ([Fig. 3, C, F, and G](#fig3){ref-type="fig"}). Cooverexpressed flag-Cul4 and DCAF12 also colocalized in nuclei ([Fig. 3 H](#fig3){ref-type="fig"}). Hence, these findings suggest that DCAF12 forms distinct nuclear complexes with Cul4.

Since there are no anti-fly DDB1 antibodies available, we tested whether overexpressed myc-tagged DDB1 colocalizes with nuclear DCAF12. Consistent with the mostly cytoplasmic localization of mammalian DDB1 ([@bib64]; [@bib44]; [@bib22]; [@bib33]), the majority of myc-DDB1 was cytoplasmic in both larval neurons and muscles and did not colocalize with nuclear DCAF12 ([Fig. 3 J](#fig3){ref-type="fig"} and Fig. S1, L and M). Cooverexpression (coOE) of myc-DDB1 with DCAF12 in muscles had no effect on nuclear DCAF12's localization (Fig. S1 M). In contrast, coOE of myc-DDB1 with DCAF12 in neurons retained DCAF12 in the cytoplasm where it partially colocalized with DDB1 (Fig. S1 M). Hence, DDB1 may shuttle DCAF12 into the nucleus to facilitate its interaction with Cul4. Consistently, KD of DDB1 abolished the focal nuclear enrichment of DCAF12 and reduced nuclear DCAF12 levels ([Fig. 3, C, F, and G](#fig3){ref-type="fig"}).

DCAF12 genetically interacts with Cul4 {#s06}
--------------------------------------

*Drosophila* Cul4 is required for cell proliferation during early development ([@bib40]). Consistently, Cul4 KD reduced larval muscle size ([Fig. 3 N](#fig3){ref-type="fig"}). Loss of DCAF12 had no major effects on early development. The size of larval muscles, number of nuclei, and synaptic growth of the NMJs were normal ([Fig. 3, K and M](#fig3){ref-type="fig"}; and Fig. S2, B and C); only the size of muscle nuclei was increased ([Fig. 3 L](#fig3){ref-type="fig"}). In contrast, DCAF12 OE in larval muscles impaired their structure and size, the size of nuclei, and synaptic growth of the NMJ ([Fig. 3, O--R](#fig3){ref-type="fig"}). OE of ΔNLS-DCAF12 had no significant effect ([Fig. 3, P--R](#fig3){ref-type="fig"}).

Most of the DCAF12 OE effects required Cul4 but not DDB1. Reducing Cul4 levels with a heterozygous null mutation suppressed both the muscle size and synaptic growth phenotypes but not nuclear size ([Fig. 3, P--R](#fig3){ref-type="fig"}). In contrast, reducing levels of DDB1 had no significant effect ([Fig. 3, P and Q](#fig3){ref-type="fig"}). Thus, these data indicate that both nuclear DCAF12 and Cul4 act in a common pathway.

DCAF12 mediates Cul4-dependent protein ubiquitination {#s07}
-----------------------------------------------------

To directly assess whether DCAF12 is either a target of Cul4-mediated ubiquitination or a cofactor of Cul4 ubiquitin ligase complexes, we examined levels of ubiquitinated proteins in *dcaf12* mutants by using antibodies that specifically detect monoubiquitinated and polyubiquitinated proteins ([@bib18]). Ubiquitinated protein clusters were present in the cytoplasm of control muscles, while their nuclei exhibited a much denser distribution ([Fig. 4 A](#fig4){ref-type="fig"}). Cul4 KD severely reduced the amount of ubiquitinated proteins in the nucleus ([Fig. 4 A](#fig4){ref-type="fig"}), which is consistent with the ubiquitin ligase--promoting function of fly Cul4 ([@bib53]).

![**DCAF12 mediates Cul4-dependent protein ubiquitination. (A and B)** Muscle nuclei (dashed circle) stained for ubiquitinated proteins (Ubi). **(C and D)** Nuclear Ubi levels in muscles (C) and number of Ubi foci (D) at NMJs (*n* ≥ 11). **(E)** Larval NMJs stained for Ubi and HRP. **(F)** Muscle nuclei stained for Ubi. **(G and H)** Number of Ubi foci per nucleus (*n* ≥ 23; *n* ≥ 7). Scale bars, 20 µm (A and E), 10 µm (B), and 5 µm (F). Graphs display means ± SEM. Statistical analysis used two-tailed unpaired *t* test (C and D) or one-way ANOVA (G and H); \*, P \< 0.05; \*\*\*, P \< 0.001.](JCB_201805099_Fig4){#fig4}

Nuclear levels of ubiquitinated proteins were reduced in *Δ51* mutants ([Fig. 4, B and C](#fig4){ref-type="fig"}), as well as levels of ubiquitinated protein foci at NMJs ([Fig. 4, D and E](#fig4){ref-type="fig"}). Conversely, DCAF12 OE increased the amount of ubiquitinated protein foci in the nucleus ([Fig. 4, F--H](#fig4){ref-type="fig"}). ΔNLS-DCAF12 OE had no significant effect relative to control ([Fig. 4 G](#fig4){ref-type="fig"}).

Reducing the gene dosage of Cul4 fully suppressed the elevated number of nuclear ubiquitinated protein foci induced by DCAF12 OE ([Fig. 4, F and H](#fig4){ref-type="fig"}) but not the increased nuclear size ([Fig. 3 R](#fig3){ref-type="fig"}). These data suggest that nuclear DCAF12 promotes Cul4-mediated ubiquitination.

Presynaptic DCAF12 is required for evoked neurotransmitter release at larval NMJs {#s08}
---------------------------------------------------------------------------------

To determine the role of DCAF12 underlying the impaired locomotion of *dcaf12* mutants ([Fig. 1 F](#fig1){ref-type="fig"}), we examined the function of larval NMJs. Loss of DCAF12 had no effect on synaptic growth, number of AZs, and levels of AZ and synaptic vesicle (SV) proteins (Fig. S2, B--F and J--L). Mutant boutons exhibited no major ultrastructural defects (Fig. S2, G--I); only the number of SVs clustered at AZs was slightly increased (Fig. S2 H).

Next, we recorded miniature excitatory postsynaptic potentials (mEPPs) and nerve-evoked EPPs. *Δ51* null mutant muscles exhibited a reduced membrane input resistance but normal resting potential (Fig. S3, I and J). Amplitudes of spontaneously occurring mEPPs were normal at heterozygous and homozygous *Δ51* NMJs ([Fig. 5, A, C, and D](#fig5){ref-type="fig"}; and Fig. S3, A and E). The frequency of mEPPs was significantly increased in homozygous *Δ51* mutants and other heterozygous and homozygous *dcaf12* alleles ([Fig. 5 E](#fig5){ref-type="fig"} and Fig. S3, D and H). However, this effect is likely due to the genetic background, as indicated by the effects of crossing in transgenes ([Fig. 5 E](#fig5){ref-type="fig"}).

![**DCAF12 is required for evoked neurotransmitter release at larval NMJs.** mEPPs and evoked EPPs were recorded from muscle 6 of the indicated genotypes in HL3 media containing 0.6 mM Ca^2+^. **(A and B)** Representative traces of mEPPs (inset) and EPPs evoked by single- (A) or paired-pulse stimulation (B). **(C--G)** Average mEPP amplitudes (C), their cumulative frequency distribution (D; *n* ≥ 270), mEPP frequency (E), EPP amplitudes (F), and quantal content (G) of control and *Δ51* (*n* ≥ 9) and *Δ51* mutants expressing DCAF12 presynaptically (*n* ≥ 11). **(H)** Plot of corrected quantal content recorded at various extracellular \[Ca^2+^\]s (*n* ≥ 4). **(I)** Paired-pulse ratio (EPP2/EPP1) for various interstimulus intervals (*n* ≥ 3). **(J--M)** EPP amplitudes and quantal content from *Δ51* mutants expressing ΔNLS-DCAF12 presynaptically (J and K; *n* ≥ 9) or DCAF12 postsynaptically (L and M; *n* ≥ 5). **(N--Q)** Effects of postsynaptic DCAF12 OE on mEPP amplitudes (N), EPP amplitudes (O), quantal content (P), and mEPP frequency (Q; *n* ≥ 7). **(R)** Cumulative frequency distribution of mEPP amplitudes (*n* ≥ 266; *n* ≥ 5). Graphs display means ± SEM. Statistical analysis used two-tailed unpaired *t* test (I and N--Q) or one-way ANOVA (C, E--G, and J--M); \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JCB_201805099_Fig5){#fig5}

Nerve-evoked EPP amplitudes at *Δ51* mutant NMJs were reduced to 50--60% of control ([Fig. 5, A and F](#fig5){ref-type="fig"}). Quantal content, an estimate of the number of SVs released per given stimulus ([@bib16]), was also reduced ([Fig. 5, G and H](#fig5){ref-type="fig"}). However, the slope of the Ca^2+^--quantal content relationship remained unchanged at low ~e~\[Ca^2+^\]s ([Fig. 5 H](#fig5){ref-type="fig"}). Paired-pulse facilitation (EPP~2/~EPP~1~) was increased ([Fig. 5, B and I](#fig5){ref-type="fig"}), indicating a reduced probability of release ([@bib59]).

Next, we performed genetic rescue experiments using Syb- and C57-Gal4 drivers for neuron- and muscle-specific expression, respectively. Presynaptically expressed DCAF12 localized to *Δ51* mutant nuclei, axons, and NMJs (Fig. S4, A and B) and hyperpolarized the muscle by ∼5 mV but had no effect on membrane input resistance (Fig. S4, C and D). Postsynaptically expressed DCAF12 localized to the muscle cytoplasm and nuclei of *Δ51* mutants (not shown) and had no effect on resting potential or input resistance (Fig. S4, F and G). Presynaptic, but not postsynaptic, expression of DCAF12 in *Δ51* mutants restored the defects in evoked EPP amplitudes and quantal content ([Fig. 5, F, G, L, and M](#fig5){ref-type="fig"}). Taken together, these findings suggest that DCAF12 is presynaptically required for a normal probability of evoked neurotransmitter release.

Finally, we tested whether nuclear or cytoplasmic DCAF12 facilitates evoked release by expressing ΔNLS-DCAF12 in *Δ51* motor neurons, which is properly localized to NMJs but absent from nuclei (Figs. S1 G and S4, A and B). Presynaptic expression of ΔNLS-DCAF12 restored evoked EPP amplitudes and partially restored quantal content at *Δ51* mutant NMJs ([Fig. 5, J and K](#fig5){ref-type="fig"}). Like full-length DCAF12 (Fig. S4, C and D), ΔNLS-DCAF12 expression hyperpolarized the muscle without affecting membrane input resistance (Fig. S4, H and I). Hence, cytoplasmic and nuclear DCAF12 are required for evoked release.

Increasing neuronal excitability by reducing Mg^2+^ in the recording solution from 10 to 4 mM ([@bib31]) partially suppressed the reduced EPP amplitudes and quantal content at homozygous *Δ51* and *B332* mutant NMJs (Fig. S3, K--N). This suggests that a decreased neuronal excitability partly underlies the reduction of evoked release at *dcaf12* mutant NMJs.

Notably, we did not interpret effects of the genetically complex *dcaf12* allele *B332.* In contrast to all other alleles, heterozygous *B332* mutants exhibited dominant effects on EPP amplitudes and quantal content (Fig. S3, B and C), while homozygous *B332* mutants exhibited reduced mEPP amplitudes (Fig. S3 E) and elevated protein levels (Fig. S1 A).

Postsynaptic OE of DCAF12 impairs synaptic transmission {#s09}
-------------------------------------------------------

Presynaptic DCAF12 OE with an elav- or Ok6-Gal4 driver had no significant effects on synaptic transmission (Fig. S4, J--N). C57-driven postsynaptic OE severely impaired muscle structure ([Fig. 3 O](#fig3){ref-type="fig"}) and function (not shown), which limited recordings of mEPPs and EPPs. Reducing Gal4 activity by raising flies at 20°C instead of 23°C to lower DCAF12 expression levels improved the electrical properties of the muscle and made stable recordings possible.

DCAF12 OE at 20°C still depolarized the muscle but had no effect on its membrane input resistance (Fig. S4, O and P). Postsynaptic DCAF12 OE reduced both mEPP and evoked EPP amplitudes ([Fig. 5, N, O, and R](#fig5){ref-type="fig"}) but had no effect on quantal content and mEPP frequency ([Fig. 5, P and Q](#fig5){ref-type="fig"}). ΔNLS-DCAF12 OE had no significant effect on mEPP amplitudes (Fig. S4 Q). Thus, nuclear DCAF12 may also have a postsynaptic role at larval NMJs.

Postsynaptic DCAF12 negatively regulates synaptic levels of GluRIIA, GluRIIC, and GluRIID subunits at larval NMJs {#s10}
-----------------------------------------------------------------------------------------------------------------

The effects of postsynaptic DCAF12 OE on mEPP amplitudes raised the possibility that DCAF12 controls postsynaptic GluRs. At larval NMJs, GluRs consist of three essential subunits (GluRIIC--GluRIIE) and a variable fourth subunit, which can be either GluRIIA or GluRIIB ([@bib14]). Immunostainings revealed increased levels of GluRIIA, GluRIIC, and GluRIID at synaptic boutons of *dcaf12^Δ51^* mutants ([Fig. 6, A, C, E, and F](#fig6){ref-type="fig"}). In contrast, GluRIIB levels were normal ([Fig. 6, A and D](#fig6){ref-type="fig"}). Similar effects were present at *B332* mutant NMJs (Fig. S2, M--P). Due to a lack of antibodies, we assessed synaptic levels of transgenically expressed GFP-tagged GluRIIE, which were normal at *Δ51* mutant NMJs ([Fig. 6, A and G](#fig6){ref-type="fig"}).

![**Postsynaptic DCAF12 regulates the subunit composition of GluR at larval NMJs. (A and B)** Synaptic boutons of NMJs stained for endogenous GluRIIA, GluRIIB, GluRIIC, GluRIID, or overexpressed GluRIIE-GFP subunits. Scale bars, 5 µm (A) and 2.5 µm (B). **(C--G)** Effect of DCAF12 deletion on synaptic levels of endogenous GluRIIA (C; *n* ≥ 9), GluRIIB (D; *n* ≥ 16), GluRIIC (E; *n* ≥ 17), GluRIID (F; *n* ≥ 13), and overexpressed GluRIIE-GFP subunits (G; *n* ≥ 7). **(H--K)** Effects of DCAF12 deletion on the size of GluRIIC-positive GluR clusters (H), GluRIIC fluorescence per cluster (I), normalized number of GluRIIC clusters to bouton area (J), and size of GluRIIA clusters (K; *n* ≥ 9). **(L--O)** Effects of presynaptic (L; *n* ≥ 11) and postsynaptic (M--O; *n* ≥ 7) expression of DCAF12 or ΔNLS-DCAF12 in *Δ51* mutants on normalized synaptic GluRIIA levels (L and M), number of GluRIIA-positive clusters per bouton area (N), and GluRIIA fluorescence per bouton (O). **(P)** Effects of vGlut OE on mEPP amplitudes (*n* ≥ 11). Control is *w^1118^*; pooled control includes UAS-vGlut transgene and Gal4 driver in a *Δ51/Df Ex7312* background. **(Q)** GluRIIA, GluRIIB, GluRIIC, GluRIID, and GluRIIE mRNA levels in *dcaf12^Δ51^* mutants normalized to control (*n* ≥ 5). Graphs display means ± SEM. Statistical analysis used two-tailed unpaired *t* test (C--K) or one-way ANOVA (L--Q); \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JCB_201805099_Fig6){#fig6}

Next, we examined effects on the density and size of all GluR clusters by probing for GluRIIC subunits. In comparison to control, the number of GluRIIC-positive clusters and their intensity was significantly increased at *Δ51* mutant boutons ([Fig. 6, I and J](#fig6){ref-type="fig"}). The number and density of GluR clusters containing only the variable GluRIIA subunit was also increased ([Fig. 6, M and N](#fig6){ref-type="fig"}), but the size of both GluRIIA- and GluRIIC-positive clusters was normal ([Fig. 6, H and K](#fig6){ref-type="fig"}). This suggests that the overall increased amount of GluR clusters is likely driven by an increased number of GluRs containing GluRIIA subunits.

There are two potential explanations for the paradox that increased levels of synaptic GluRs at *Δ51* mutant NMJs do not increase mEPP amplitudes. First, the increase in GluRs could be triggered by a compensatory mechanism counteracting potentially reduced SV glutamate levels. Alternatively, postsynaptic DCAF12 may facilitate the removal of dysfunctional or abnormally located GluR subunits. To distinguish between these possibilities, we tested whether presynaptic or postsynaptic DCAF12 is required for the down-regulation of GluRs.

Postsynaptic expression of DCAF12 in *Δ51* mutants restored normal GluRIIA levels and reversed the elevated number of GluRIIA-containing GluR clusters to levels below control ([Fig. 6, B, M, and N](#fig6){ref-type="fig"}) but had no effect on mEPP amplitudes (Fig. S4 E). Postsynaptic expression of ΔNLS-DCAF12 failed to restore GluR levels ([Fig. 6 O](#fig6){ref-type="fig"}), indicating that nuclear DCAF12 is required for the regulation of synaptic GluRs. Presynaptic DCAF12 expression neither restored GluR levels ([Fig. 6 L](#fig6){ref-type="fig"}) nor increased mEPP amplitudes ([Fig. 5 C](#fig5){ref-type="fig"}), as it would be expected if an increase in GluRs were to counteract reduced vesicular glutamate. These findings exclude a presynaptic mechanism and suggest that postsynaptic, nuclear DCAF12 negatively regulates synaptic levels of GluRIIA subunits.

To determine whether the abnormally accumulating GluRs of *Δ51* mutant NMJs are partially dysfunctional, we tested whether increasing vesicular glutamate by presynaptic OE of the vesicular glutamate transporter (vGlut; [@bib9]) has differential effects on mEPP amplitudes at WT and *Δ51* mutant NMJs. D42-driven expression increased vGlut levels at control and *Δ51* mutant NMJs to a similar extent (Fig. S4 R). However, vGlut OE increased mEPP amplitudes in controls to a significantly larger degree than in *Δ51* mutants ([Fig. 6 P](#fig6){ref-type="fig"}). This suggests that GluRs in *Δ51* deletion mutants are at least partially dysfunctional, which may arise from a failure to remove dysfunctional GluRs or from a defective alignment of the accumulating GluRs with AZs.

Finally, we tested whether DCAF12 controls the expression of GluR subunits on a transcriptional level by assaying mRNA levels of all five GluR subunits using quantitative RT-PCR. Only GluRIID mRNA levels were significantly elevated in *Δ51* ([Fig. 6 Q](#fig6){ref-type="fig"}) and *B332* muscles (Fig. S2 Q). Thus, nuclear DCAF12 likely controls GluRIID mRNA expression.

Postsynaptic DCAF12 controls the synaptic ratio of GluRIIA/B subunits by exclusively down-regulating synaptic GluRIIA {#s11}
---------------------------------------------------------------------------------------------------------------------

The ratio of the nonessential GluRIIA/B subunits is a critical parameter of synapse maturity at fly NMJs ([@bib63]; [@bib36]; [@bib12]). Since loss of DCAF12 affected GluRIIA but not GluRIIB subunits ([Fig. 6, C and D](#fig6){ref-type="fig"}), we tested whether this would also be the case for DCAF12 OE. Indeed, muscle-specific DCAF12 OE reduced the levels of GluRIIA but not GluRIIB at synaptic boutons ([Fig. 7, A, D, and E](#fig7){ref-type="fig"}). Specifically, it decreased the number and density of GluRIIA-containing GluRs, while the size of GluRIIA clusters increased ([Fig. 7, F--H](#fig7){ref-type="fig"}). The down-regulation of GluRIIA levels induced by DCAF12 OE was dependent on its nuclear localization since ΔNLS-DCAF12 OE did not reduce GluRIIA levels but instead slightly increased them ([Fig. 7 D](#fig7){ref-type="fig"}).

![**Postsynaptic nuclear DCAF12 controls the synaptic ratio of GluRIIA/IIB subunits. (A--C)** Larval NMJs stained for endogenous GluRIIA and GluRIIB (A) and GFP-tagged GluRIIA and GluRIIB expressed in WT or *Δ51* (B) or coexpressed with DCAF12 (C). Scale bar, 5 µm. **(D--H)** Effects of postsynaptic DCAF12 (D--H) or ΔNLS-DCAF12 OE (D) on synaptic levels of endogenous GluRIIA subunits (D and F--H; *n* ≥ 7) or GluRIIB subunits (E; *n* ≥ 5). **(I and J)** Effects of DCAF12 deletion on GluRIIA-GFP (I) and GluRIIB-GFP (J) expression levels (*n* ≥ 9). **(K and L)** Effects of DCAF12 coOE on GluRIIA-GFP (C and K) and GluRIIB-GFP (C and L) expression levels (*n* ≥ 11). **(M--Q)** Traces (M) of mEPPs and EPPs and quantification of mEPP amplitudes (N), EPP amplitudes (O), mEPP/EPP ratio (P), and synaptic GluRIIA levels (Q) from controls and trans-heterozygous *glurIIA^SP16/+^*; *dcaf12^Δ51/+^* double mutants (*n* ≥ 7). Graphs display means ± SEM. Statistical analysis used one-way ANOVA (D, F--H, and N--Q), two-tailed unpaired *t* test (I and L), or a Mann--Whitney test (E, J, and K); \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JCB_201805099_Fig7){#fig7}

To confirm that DCAF12 does not regulate GluRIIA mRNA expression, we expressed GFP-tagged GluRIIA/B subunits in muscles of DCAF12 loss and gain of function mutants. Since Gal4-driven transcription is largely independent of endogenous control mechanisms, phenotypic effects on GluR-GFP expression levels are not likely to be caused by regulating mRNA expression. Postsynaptic expression levels of GluRIIA-GFP at Δ*51* mutant NMJs were increased to 154% of control, while synaptic GluRIIB-GFP levels were only slightly increased ([Fig. 7, B, I, and J](#fig7){ref-type="fig"}). Similar effects were seen in *B332* mutants (Fig. S2, R and S). CoOE of DCAF12 with GluRIIA-GFP or GluRIIB-GFP decreased GluRIIA-GFP levels to 60% of control, while GluRIIB-GFP levels were only marginally increased ([Fig. 7, C, K, and L](#fig7){ref-type="fig"}). The latter is probably an indirect effect because the decreased GluRIIA levels may generate extra synaptic binding sites for GFP-GluRIIB due to a reduced competition with GluRIIA subunits for access to GluRIIC/D/E complexes ([@bib47]). Taken together, these findings confirm that nuclear DCAF12 indirectly controls synaptic GluRIIA subunits through a cytoplasmic factor, consistent with the normal GluRIIA mRNA levels in *Δ51* mutants.

A role of DCAF12 for GluRIIA function was further indicated by genetic interactions. Individual heterozygous *glurIIA^SP16/+^* or *dcaf12^Δ51/+^* deletions had no effect on mEPP and EPP amplitudes ([Fig. 7, M--O](#fig7){ref-type="fig"}; and Fig. S3, A and B). GluRIIA levels in the transheterozygous double mutants were not changed ([Fig. 7 Q](#fig7){ref-type="fig"}). However, both mEPP and EPP amplitudes were proportionally decreased at transheterozygous double-mutant NMJs, since the ratio of EPP/mEPP amplitudes was not affected ([Fig. 7, N--P](#fig7){ref-type="fig"}).

DCAF12's regulation of synaptic GluRIIA levels depends on Cul4 {#s12}
--------------------------------------------------------------

Since nuclear DCAF12 controls synaptic GluRIIA levels, we speculated that DCAF12's role may require Cul4. Indeed, Cul4 KD in muscles increased the amount of synaptic GluRIIA subunits at larval NMJs ([Fig. 8 F](#fig8){ref-type="fig"}), indicating that Cul4 is required for the synaptic expression of GluRIIA subunits.

![**DCAF12 controls synaptic GluRIIA levels in a Cul4-dependent manner. (A--C)** Effects of postsynaptic DCAF12 OE and reduced Cul4 on synaptic GluRIIA levels (A and B; *n* ≥ 11) and mEPP amplitudes at larval NMJs (C; *n* ≥ 9). Scale bar, 5 µm. **(D and E)** Effects on resting potential (D) and input resistance (E) of muscle (*n* ≥ 9). **(F)** Effect of muscle Cul4 KD on synaptic GluRIIA levels (*n* ≥ 13). **(G--I)** mEPP amplitudes (G), EPP amplitudes (H), and quantal content (I) of heterozygous *glurIIA*-*cul4* double mutants (*n* ≥ 9). Graphs display means ± SEM. Statistical analysis used one-way ANOVA (B--E and G--I) or two-tailed unpaired *t* test (F); \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JCB_201805099_Fig8){#fig8}

Cul4 was also required for the effects of postsynaptic DCAF12 OE on synaptic GluRIIA levels and mEPP amplitudes. Reducing the gene dosage of Cul4 by one copy restored both synaptic GluRIIA levels and mEPP amplitudes to control levels ([Fig. 8, A--C](#fig8){ref-type="fig"}) but had no significant effect on the resting potential and membrane input resistance relative to DCAF12 OE ([Fig. 8, D and E](#fig8){ref-type="fig"}).

A critical role of Cul4 was further supported by genetic interactions. mEPP and EPP amplitudes were normal at both heterozygous *glurIIA^SP16/+^* and *cul4^11L^*^/+^ NMJs but significantly decreased at transheterozygous double-mutant *glurIIa^SP16/+^; cul4^11L^*^/+^ NMJs ([Fig. 8, G and H](#fig8){ref-type="fig"}). Quantal content remained normal ([Fig. 8 I](#fig8){ref-type="fig"}). These data indicate that nuclear DCAF12 controls postsynaptic GluRIIA levels by a Cul4-dependent mechanism.

DCAF12 is required for homeostatic potentiation of evoked release at larval NMJs {#s13}
--------------------------------------------------------------------------------

Next, we explored whether DCAF12 mediates homeostatic potentiation of synaptic transmission. This form of synaptic plasticity maintains normal postsynaptic excitation in response to a decrease in postsynaptic neurotransmitter receptor sensitivity and requires transsynaptic signaling to up-regulate evoked release ([@bib55]; [@bib15]; [@bib10]; [@bib71]; [@bib17]). At fly NMJs, loss of both GluRIIA and GluRIIC subunits triggers a homeostatic increase in quantal content to maintain evoked EPP amplitudes ([@bib55]; [@bib15]; [@bib47]; [@bib4]).

To test whether homeostatic signaling requires DCAF12, we generated homozygous *GluRIIA-DCAF12* double-mutant flies, which unexpectedly died at much earlier developmental stages than each individual mutant. Only a very small number survived to the early third-instar stage. These exhibited reduced EPP amplitudes and quantal content (Fig. S5, A--D), as seen in individual *dcaf12* mutants. Accordingly, loss of GluRIIA subunits in the double mutants did not trigger a homeostatic response. However, this could have been a consequence of the primary evoked release defect of *dcaf12* mutants.

To bypass the confounding problem of impaired basal transmission, we tested whether reducing the gene dosage of DCAF12 suppresses the compensatory increase in quantal content of homozygous *glurIIA^SP16^* mutants ([Fig. 9, D and H](#fig9){ref-type="fig"}). In comparison to individual *glurIIA^SP16^* mutants, removing one gene copy of DCAF12 had no effect on mEPP amplitudes and the resting membrane potential ([Fig. 9, A, B, E, and F](#fig9){ref-type="fig"}). However, it significantly reduced evoked EPP amplitudes due to a partial suppression of the homeostatic increase in the ratio of mEPP/EPP amplitudes and quantal content ([Fig. 9, A, C, D, and G--I](#fig9){ref-type="fig"}).

![**Presynaptic DCAF12 is required homeostatic potentiation.** mEPPs and EPPs were recorded from larval muscle 6 of indicated genotypes in HL3 media containing 0.6 mM Ca^2+^. **(A)** Representative traces of mEPPs (inset) and EPPs. **(B--I)** Effects of reducing DCAF12 in *glurIIA^SP16^* mutants on average and normalized mEPP amplitudes (B and F), EPP amplitudes (C and G), quantal content (D and H), EPP/mEPP ratio (I), and muscle resting potential (E; *n* ≥ 8). **(J--M)** Effects of genetic rescue of DCAF12 on normalized mEPP amplitudes (J), EPP amplitudes (K), quantal content (L), and EPP/mEPP ratio (M; *n* ≥ 14). Graphs display means ± SEM. Statistical analysis used one-way ANOVA (B--M); \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JCB_201805099_Fig9){#fig9}

Next, we performed genetic rescue experiments. Rescue controls containing either a silent UAS-DCAF12 transgene or the Syb-Gal4 driver had no effect on mEPPs, EPPs, and quantal content ([Fig. 9, J--M](#fig9){ref-type="fig"}). Presynaptic expression of DCAF12 in *glurIIA^SP16^; dcaf12^Δ51/+^* double mutants had no effect on mEPP amplitudes ([Fig. 9, A, and J](#fig9){ref-type="fig"}; and Fig. S5 E). However, it restored evoked EPP amplitudes to levels that were similar to control and *glurIIA^SP16^* mutants ([Fig. 9, A and K](#fig9){ref-type="fig"}, and Fig. S5 F). The effect on EPPs was due to a rescue of the homeostatic increase in quantal content, which was similar to that of *glurIIA^SP16^* mutants ([Fig. 9, L and M](#fig9){ref-type="fig"}; and Fig. S5 G). Presynaptic DCAF12 expression caused a slight hyperpolarization of the muscle similar to that of individual *glurIIA^SP16^* mutants (Fig. S5 H). Postsynaptic rescue experiments were deemed not informative due to the confounding effect of postsynaptic DCAF12 OE on GluRs. These data suggest that presynaptic DCAF12 is required for the expression of homeostatic potentiation at larval NMJs.

Discussion {#s14}
==========

Our study identified novel synaptic roles of DCAF12, a potential cofactor of Cul4 E3 ligase ([@bib2]; [@bib35]; [@bib52]). Loss of DCAF12 arrests development and impairs larval locomotion. Presynaptic DCAF12 facilitates neurotransmitter release and synaptic homeostasis, while postsynaptic nuclear DCAF12 is required to maintain synaptic GluRIIA, GluRIIC, and GluRIID levels. In addition, we demonstrate a critical role of nuclear DCAF12 for Cul4-mediated protein ubiquitination and show that DCAF12 together with Cul4 negatively controls synaptic GluRIIA levels.

Nuclear DCAF12 associates with Cul4 promoting protein ubiquitination {#s15}
--------------------------------------------------------------------

Affinity purifications using Cul4A, DDB1, or chromatin-associated DDA1 indicated that DCAF12 can associate with Cul4A/B complexes together with components of the COP9 signalosome ([@bib2]; [@bib52]), which likely inactivates various Cullin ligases by deneddylation ([@bib72]; [@bib74]). However, the role of Cul4-associated DCAF12 has remained speculative. DCAF12 could link ubiquitination substrates to Cul4 ([@bib2]; [@bib26]; [@bib29]), could modulate the E3 ubiquitin ligase activity, or could be a ubiquitination target of Cul4.

We confirmed the biochemical interaction of DCAF12 with DDB1 in S2 cells and with Cul4 in adult fly brains. In addition, immunostainings suggest that DCAF12 forms a nuclear protein complex with Cul4 in muscles, where they are enriched in distinct foci. This focal enrichment requires normal levels of Cul4, DDB1, and DCAF12. The nature of the DDB1 interaction with DCAF12 and Cul4 remains to be further explored, but it is possible that DDB1 may stabilize DCAF12-Cul4 complexes and/or aid shuttling of DCAF12 into muscle nuclei.

Further genetic studies showed that loss of DCAF12 and Cul4 reduced ubiquitinated nuclear protein levels. Vice versa, DCAF12 OE increased nuclear protein ubiquitination. This DCAF12 OE effect was suppressed by reducing the gene dosage of Cul4, indicating that DCAF12 promotes Cul4 protein ubiquitination. The possibility that DCAF12 is ubiquitinated by Cul4 complexes for degradation can be excluded since Cul4 KD had no effect on DCAF12 levels.

DCAF12 is required for pre- and postsynaptic function at larval NMJs {#s16}
--------------------------------------------------------------------

We suggest that neuronal DCAF12 is cell-autonomously required for evoked neurotransmitter release because DCAF12 expression in *dcaf12* mutant motor neurons fully restored the loss of evoked release at NMJs. DCAF12 likely promotes a Ca^2+^-dependent step of release since its loss reduced the Ca^2+^ sensitivity of release and increased paired-pulse facilitation. Because cytoplasmically localized ΔNLS-DCAF12 partially restored evoked release in *dcaf12* mutants, we suggest that DCAF12 is required for both nuclear and cytoplasmic mechanisms in neurons. Next to controlling mechanisms of evoked release, DCAF12 may also facilitate neuronal excitability by regulating ion channels since lowering \[Mg^2+^\] improved evoked release in *dcaf12* mutants. Consistently, Cul4 ubiquitinates large-conductance Ca^2+^-activated potassium (BK) and CLC-1 chloride channels ([@bib7]; [@bib67]).

Postsynaptically, DCAF12 is required for a normal composition of synaptic GluRs by negatively controlling the levels of GluRIIA, GluRIIC, and GluRIID, which accumulated in *dcaf12* mutants. Paradoxically, the increased levels of synaptic GluRs at *dcaf12* null mutant NMJs did not increase mEPP amplitudes. This raised the possibility that the accumulating GluRs are either dysfunctional or the product of a compensating response to a presynaptic defect in the glutamate content of SVs. However, the latter was not the case since presynaptic expression of DCAF12 in *dcaf12* mutants did not affect GluR levels or increased mEPP amplitudes. Only postsynaptic expression restored normal synaptic GluR levels, as exemplified by GluRIIA subunits. Hence, the abnormally accumulating GluRs are likely dysfunctional or mislocalized. This possibility was supported by the differential effects of presynaptic vGlut OE, which increased mEPP amplitudes in controls to a significantly larger degree than in *Δ51* mutants.

Finally, RT-PCR assays showed that only GluRIID mRNA levels are significantly elevated in *dcaf12* muscles, indicating that DCAF12 controls synaptic GluRIID expression on a transcriptional level. In contrast, nuclear DCAF12 may control at least synaptic GluRIIA levels through the transcriptional control of an unknown postsynaptic factor that regulates synaptic GluRIIA levels. This idea is supported by the effects of altered DCAF12 levels on the Gal4-driven expression of GluRIIA-GFP.

DCAF12 controls the ratio of GluRIIA/B subunits in a Cul4-dependent manner {#s17}
--------------------------------------------------------------------------

Loss and OE of DCAF12 exclusively affected GluRIIA but not GluRIIB. This differential effect is particularly interesting because these subunits determine the Ca^2+^ permeability and kinetic properties of GluRs ([@bib15]; [@bib63]; [@bib24]). Moreover, the ratio of GluRs containing either GluRIIA or GluRIIB subunits determines the developmental maturity of postsynaptic densities of larval NMJs and is critical for activity-dependent synaptic plasticity ([@bib55]; [@bib15]; [@bib63]).

The elevated synaptic levels of GluRIIA subunits at both *dcaf12* mutant NMJs could have been due to a presynaptic defect since the developmental switch toward a more balanced GluRIIA/B ratio is induced by the maturation of the presynaptic AZ and subsequent association of additional Ca^2+^ channels ([@bib63]; [@bib68]). However, this is unlikely to be the case for three reasons: First, *dcaf12* mutant NMJs exhibited a normal number of AZs and BRP levels. Second, GluRIIA levels of *dcaf12* null mutants were restored by postsynaptic but not presynaptic expression of normal DCAF12. Third, postsynaptic DCAF12 OE decreased synaptic GluRIIA levels. Hence, postsynaptic DCAF12 is likely a negative regulator of synaptic GluRIIA levels. Genetic interactions between heterozygous deletions of *glurIIA* and *dcaf12* further support this notion.

Consistent with DCAF12's nuclear localization, genetic rescue and OE experiments using ΔNLS-DCAF12 confirmed that nuclear DCAF12 controls synaptic GluRIIA levels. Since *dcaf12* mutants had no effect on GluRIIA mRNA levels, nuclear DCAF12 controls synaptic GluRIIA levels indirectly through a third factor. This was substantiated by the effects of loss and OE of DCAF12 synaptic GFP-GluRIIA levels, which were altered like endogenous GluRIIA levels.

Mechanistically, DCAF12's inhibitory control of GluRIIA expression depends on Cul4, which is indicated by three critical observations: (1) Cul4 KD in muscles increased synaptic GluRIIA levels at the NMJ. (2) Heterozygous *cul4-glurIIA* double mutants exhibited reduced mEPP amplitudes, indicating that Cul4 and GluRIIA act in a common pathway. (3) Reducing the gene dosage of Cul4 fully suppressed the increased levels of synaptic GluRIIA subunits induced by DCAF12 OE. Taken together, we suggest that a nuclear DCAF12-Cul4 E3 ubiquitin ligase complex controls a transcription factor for the expression of an unknown cytoplasmic factor down-regulating synaptic GluRIIA levels. An intriguing synaptic candidate whose mRNA expression may be controlled by DCAF12-Cul4 is the multimeric Cul3-Kel8 ubiquitin ligase complex, which ubiquitinates the synaptic GluR subunit GLR-1 for degradation in *Caenorhabditis elegans* ([@bib62]).

DCAF12 is required for synaptic homeostasis at larval NMJs {#s18}
----------------------------------------------------------

Homeostatic synaptic plasticity is critical for maintaining stable neuronal networks ([@bib71]; [@bib11]). Several pieces of genetic evidence suggest that presynaptic DCAF12 is critically required for synaptic homeostasis at larval NMJs. (1) Analysis of homozygous *glurIIA-dcaf12* double mutants revealed no homeostatic response as it is typically observed in individual *glurIIA* mutants. (2) Reducing the gene dosage of DCAF12 impaired the compensatory homeostatic increase in quantal content of homozygous *glurIIA* mutants. (3) Presynaptic expression of DCAF12 restored quantal content, indicating that presynaptic DCAF12 is required for maintaining synaptic homeostasis. Notably, DCAF12 is required at the larval NMJ for two independent mechanisms of synaptic plasticity. Since proteasomal function is required for homeostatic potentiation ([@bib73]), it is conceivable that DCAF12 may regulate presynaptic homeostasis via a ubiquitin- and Cul4-dependent mechanism.

In conclusion, this study extends the repertoire of proteins facilitating synaptic function and plasticity. It also illuminates the importance of expanding our understanding of Cul4-mediated ubiquitination for GluR function and plasticity. A further understanding of DCAF12's pleiotropic synaptic functions may shed light on how potentially cross-linked molecular pathways work together to orchestrate stable cellular networks and how alterations in these pathways can lead to Cul4B-mediated intellectual disability in humans ([@bib70]; [@bib75]).

Materials and methods {#s19}
=====================

*Drosophila* stocks and husbandry {#s20}
---------------------------------

All flies were raised at 23°C on standard cornmeal medium with a 12/12-h light--dark cycle unless otherwise specified. Strains P{XP}CG18547\[d05047\], P{WH}Tk\[f06233\], P{XP}CG18547\[d05047\], PBac{WH}f00760, and P{XP}d08712 were obtained from Bloomington *Drosophila* Stock Center (BDSC) and the Exelixis collection at Harvard Medical School. UAS hairpin strains to KD DCAF12 (43758), DDB1/piccolo (44974 and 44976), and Cul4 (105668KK) were obtained from the Vienna *Drosophila* RNAi Center. The *cul4^11L^* and *ddb1^EY01408^* strains were obtained from Robert Duronio (University of North Carolina, Chapel Hill, NC). The Gal4 driver strains C57/BG57-Gal4 and nSyb-Gal4 were obtained from Vivian Budnik (University of Massachusetts, Amherst, MA) and Hugo Bellen (Baylor College of Medicine, Houston, TX), respectively. GFP-tagged UAS transgenes expressing GFP-GluRIIA, GFP-GluRIIB, and GFP-GluRIIE were obtained from Stephan Sigrist (Freie Universität Berlin, Berlin, Germany). UAS-vGlut2 was obtained from Aaron DiAntonio (Washington University, St Louis, MO). The *glurIIA^SP16^ strain* was obtained from C. Andrew Frank (University of Iowa, Iowa City, IA).

Deficiency mapping {#s21}
------------------

Standard deficiency mapping using the BDSC deficiency kit for chromosome 3R was used to map the genetic locus of the lethal alleles *B332* and *B417* to the deletion *Df(3R)Exel7312* by testing the viability of the respective heteroallelic combinations. The small deletion alleles *Δ87A4-1*, *Δ87A4-2*, and *Δ87A5-1* were used to further narrow down the mapping interval. These alleles were generated by FRT-mediated recombination ([@bib54]). Specifically, *Δ87A4-1* was generated by crossing the FRT insertion P{XP}CG18547\[d05047\] to a heat shock--driven FLP recombinase (hs-FLP; *P{hsFLP}1, y^1^ w^1118^; Dr^Mio^/TM3*) at 25°C. F1 progeny (*P{hsFLP}1, y^1^ w^1118^; P{XP}CG18547/TM3*) containing hs-FLP and the FRT insertion were crossed to P{WH}Tk\[f06233\] to generate F2 progeny containing two FRT insertions in trans in the presence of hs-FLP (*P{hsFLP}1, y^1^ w^1118^; P{XP}CG18547/P{WH}Tk*). After 2 d, crosses (parents and progeny) were subjected to a 1-h heat shock by placing the bottles into a 37°C water bath. Parents were removed after 1 d, and bottles were subjected to four more daily 1-h heat shocks. Progeny were raised to adulthood, and individual virgin females were crossed to marked balancer chromosomes. Individual male progeny were then crossed to females to generate additional progeny for PCR confirmation analysis and to balance the stocks. The deletions *Δ87A4-2 and Δ87A5-1* were generated accordingly using the FRT insertions P{XP}CG18547\[d05047\] and P{WH}f00989, and PBac{WH}f00760 P{XP}d08712, respectively.

DCAF12 antibody generation {#s22}
--------------------------

*Drosophila* DCAF12 cDNA was PCR amplified from clone LD21841 (*Drosophila* Genomics Resource Center \[DGRC\]) using forward (5′-GAGA[GCTAGC]{.ul}TTCAACGGGATGGTGAGAACCATCCGCG-3′) and reverse primers (5′-GA[GAATTC]{.ul}CTATTGCCAAACGCCCGCATAGTTGCC-3′) containing *Nhe*I and *Eco*RI restriction sites (sites are underlined in primer sequences), respectively. DCAF12 cDNA was then subcloned in frame to the N-terminal 6xHis-tag of the vector pET28b (Novagen) using *Nhe*I and *Eco*RI restriction enzymes. The recombinant fusion protein was expressed in *Escherichia coli* BL21 (DE3) cells (Invitrogen) and purified from cell lysates using the PrepEase His-tagged protein purification kit (Affymetrix/USB). Two guinea pigs (GP11 and GP12) were immunized for polyclonal antibody production using a 90-d protocol (Cocalico Biologicals). The obtained antisera were screened by immunohistochemistry and Western blotting using larval protein extracts.

Generation of UAS transgenes {#s23}
----------------------------

To generate a transgene encoding full-length DCAF12, cDNA was PCR amplified from clone LD21841 (DGRC) with primers containing either an *Eco*RI and Kozak sequence (5′-G[GAATTC]{.ul}GCCACCATGTTCAACGGGATGGTGAGAACCATCCGCGACAGCG-3′) or a *Xho*I site (5′-GC[CTCGAG]{.ul}CTATTGCCAAACGCCCGCATAGTTGCCCACCAAAGTCGC-3′) and subcloned into a pUAST vector ([@bib3]), using *Eco*RI and *Xho*I sites.

To generate a transgene expressing ΔNLS-DCAF12, cDNA was PCR amplified from clone LD21841 using forward and reverse primers containing either a flanking *Not*I and Kozak sequence (5′-GAGA[GCGGCCGC]{.ul}GACAAAATGCGACAGGAGCGTAGACGAAAACCGG-3′) or a *Xba*I site (5′-GAGA [TCTAGA]{.ul}CTATTGCCAAACGCCCGCATAGTTGCCC-3′), and subcloned into a pUAST vector using *Not*I and *Xba*I sites. The resulting cDNA transgenes encode an N-terminally truncated DCAF12 protein, which lacks the first 35 amino acids, including 7 amino acids (underlined) of the NLS ([RRAKQRA]{.ul}MRQERRRK) and starts at position M36.

To generate a transgene encoding N-terminal FLAG-tagged Cul4, cDNA was PCR amplified from clone LP02965 (DGRC) using forward and reverse primers containing a flanking *Not*I (5′-GAGA[GCGGCCGC]{.ul}AGTGCGGCCAAGAAGTACAAGCCCATGG-3′) or *Kpn*I site (5′-GAGA[GGTACC]{.ul}TTATGCCACATAGTTGTATTGGTTTTGATTATCCTTGTCTCGCTCC-3′) and subcloned into a FLAG-tagged pUAST vector using *Not*I and *Kpn*I sites. pUAST-FLAG was generated by annealing two complementary oligomers encoding the FLAG epitope (5′-AATTCACCGGTGACAAAATGGATTATAAAGATGATGATGATAAAAGC-3′; 5′-GGCCGCTTTTATCATCATCATCTTTATAATCCATTTTGTCACCGGTG-3′), cutting them with *Eco*RI and *Not*I and cloning them into an equally cut pUAST vector.

To generate a transgene encoding N-terminal myc-tagged DDB1/piccolo, a 6x-myc tag-containing pUAST vector was generated PCR-amplifying a 6x-myc tag sequence from a pTMW vector (DGRC) using primers containing EcoRI (5′-TA[GAATTC]{.ul}GACAAAAGGCCTGTCTAGAGAAGCTCCGCCACC-3′) or *Bgl*II sites (5′-TA[AGATCT]{.ul}CGTTTCTCGTTCAGCTTTTTTGTACAAACTTGTATACCGGTG-3′). The amplified 6x-Myc tag DNA was cut with *Eco*RI and *Bgl*II and subcloned into a pUAST vector. DDB1 cDNA was PCR amplified from clone LD08715 (DGRC) using primers containing flanking *Not*I (5′-TA[GCGGCCGC]{.ul}TTCGCATCACTACGTGGTGACGGCGC-3′) or *Kpn*I sites (5′-TA[GGTACC]{.ul}TCAATGCATGCGCGTGAGGTCCTCGAC-3′). The amplified DDB1 cDNA was cut with *Not*I and *Kpn*I and inserted in frame to the 6x-myc tag sequence of the modified pUAST vector.

pUAST-x plasmids were injected into *w^1118^* embryos (Rainbow Transgenic Flies). At least two independent recombinant strains were obtained for each transgene. Recombinant flies were out-crossed to *w^1118^* to exchange nonrecombinant chromosomes. Homozygous strains containing UAS-transgenes were established in a WT control (*w^1118^*) and/or *dcaf12* mutant genetic background.

Generation of a CRISPR-mediated DCAF12 deletion allele {#s24}
------------------------------------------------------

A deletion allele of DCAF12 (Δ51) was generated by using the CRISPR/CAS9 System. CRISPR target sites for DCAF12 were identified using the CRISPR Optimal Target Finder Tool ([@bib21]). Two chiRNAs targeting the 5′ and 3′ ends of DCAF12 were used to generate a large deletion of the *dcaf12* gene. Plasmids encoding chiRNAs 1 (oligo 1--2) and 2 (oligo 3--4) were generated by using the U6-gRNA CRISPR protocol ([@bib20]) and the following PCR primers: oligo 1, 5′-CTTCGTAGACTACAGTGGAACTAC-3′; oligo 2, 5′-AAACGTAGTTCCACTGTAGTCTAC-3′; oligo 3, 5′-CTTCGATTTATAGTCTGATCTATA-3′; and oligo 4, 5′-AAACTATAGATCAGACTATAAATC-3′. The chiRNA plasmids were injected into CAS9 expressing embryos (*y^1^ M{vas-Cas9}ZH-2A w^1118^/FM7c*; BDSC no. 51323) to generate DCAF12 deletion animals (Rainbow Transgenic Flies). The extent of the deletion was confirmed by PCR analysis and sequencing using the forward primers GFwd1 (5′-GAAAGCGATGGCCTATCGTTAGGGATGAACG-3′) and PFwd1 (5′-CGCACCACCATTTTTGTTTGCGGATGATAACCCG-3′), and the reverse primer R1 (5′-CCACACCCGTTGTGTTGAGTGCCCT-3′).

Quantitative RT-PCR {#s25}
-------------------

RNA was isolated from muscle extracts of third-instar larvae reared at 23°C using the Quick-RNA Microprep Kit with on-column DNase treatment (Zymo Research). cDNA synthesis was performed with a SuperScript VILO cDNA Synthesis Kit (no. 11754050; Thermo Fisher Scientific). Quantitative PCR was conducted with a Power SYBR Green PCR Master Mix (no. 4368577; Thermo Fisher Scientific) using a StepOnePlus Real Time PCR System (Applied Biosystems). Melt curve analysis verified the presence of a single product for all reactions. Mean cycle threshold (CT) of triplicate reactions was used to determine relative expression of target genes using 2-ΔCT method ([@bib57]). The following primer pairs were used: GluRIIA, forward: 5′-CCACTGGGCTCTGATTACCG-3′; reverse: 5′-CCAGAACAAGAAACACGCCG-3′; GluRIIB, forward: 5′-GGAGAAGATTCCACCCATGCT-3′; reverse: 5′-TTGAATCCCGACTTTGGCGA-3′; GluRIIC, forward: 5′-GGACTGGGAGAACCCACATC-3′; reverse: 5′-CATTCGCACCTGTGGACTTC-3′; GluRIID, forward: 5′-TACTCGAATACCAGAGGACGGA; reverse: 5′-GATGAGGCCCAGGCGAATG-3′; GluRIIE, forward: 5′-TGGAGCCTTTTTAGCATTCACA-3′; reverse: 5′-GTCGGTGAGCAGACCTATGG-3′; and RP49, forward: 5′-ATGCTAAGCTGTCGCACAAATG-3′; reverse: 5′-GTTCGATCCGTAACCGATGT-3′.

Immunostainings and confocal imaging {#s26}
------------------------------------

Wandering third-instar larvae were dissected in Sylgard-coated dishes containing HL3 solution (70 mM NaCl, 5 mM KCl, 10 mM MgCl~2~, 10 mM NaHCO~3~, 5 mM Trehalose, 115 mM sucrose, and 5 mM Hepes, pH 7.3) and fixed for 20 min in 4% formaldehyde (Electron Microscopy Sciences) in PBS (pH 7.3) at RT. GluRIIA and vGlut stainings required fixation for 3--5 min with Bouin's Fix (Ricca Chemical Company). After washing three times for 10 min in PBS supplemented with 0.2% Triton X-100 (PBST) at RT, the preparation was incubated with primary antibodies diluted in PBST overnight at 4°C, washed three times for 10 min in PBST at RT, incubated with secondary antibodies diluted in PBST for 1--2 h at RT, and washed two times with PBST for 10 min at RT. Confocal images were acquired the same day; otherwise, preparations were postfixed.

The following antibodies and dilutions were used: guinea pig anti-DCAF12 GP11, 1:20,000; guinea pig anti-DCAF12 GP12, 1:20,000; rabbit anti-Cul4, 1:1,000 ([@bib40]; cat. no. Cul4, RRID: AB_2568621); mouse anti-Lamin-C, 1:250 (Developmental Studies Hybridoma Bank \[DSHB\]; cat. no. lc28.26, RRID: AB_528339); mouse anti-CSP, 1:250 (DSHB; cat. no. DCSP-1 \[ab49\], RRID: AB_2307340); rabbit anti-Syt1, 1:500 ([@bib41]; cat. no. Syt1, RRID: AB_2568644); mouse anti-Brp, 1:500 (DSHB; cat. no. nc82, RRID: AB_2314866); mouse anti-GluRIIA, 1:500 (DSHB; cat. no. 8B4D2 \[MH2B\], RRID: AB_528269); mouse anti-discs large (DLG), 1:5,000 (DSHB; cat. no. 4F3, RRID: AB_528203); rabbit anti-vGlut, 1:10,000 (Aaron DiAntonio); rabbit anti-GluRIIB, 1:500 ([@bib48]; cat. no. GluRIIB, RRID: AB_2568753); rabbit anti-GluRIIC, 1:5,000 (Aaron DiAntonio); rabbit anti-GluRIID, 1:2,000 ([@bib58]; cat. no. GluRIID, RRID: AB_2569238); mouse anti-ubiquitin-conjugated protein, 1:5,000 (Enzo Life Sciences; cat. no. BML-PW8810, RRID: AB_10541840); mouse anti-FLAG, 1:500 (Sigma-Aldrich; cat. no. P2983, RRID: AB_439685); mouse anti-Myc, 1:250 (DSHB; cat. no. 9E 10, RRID, AB_2266850); mouse anti-Repo, 1:100 (DSHB; cat. no. 8D12 anti-Repo, RRID: AB_528448); mouse anti-Futsch, 1:1,000 (DSHB; cat. no. 22c10, RRID: AB_528403); rabbit anti-SMT3, 1:1,000 ([@bib37]; cat. no. smt3, RRID: AB_2568554); rabbit anti-Lola, 1:1,000 ([@bib19]; cat. no. lola, RRID: AB_2567779); rabbit anti-pMAD, 1:1,000 (Carl-Henrik Heldin, Göteborg University, Göteborg, Sweden; cat. no. pMad, RRID: AB_2617125); rabbit anti-coilin, 1:1,000 ([@bib42]; cat. no. coil, RRID: AB_2568646); anti-γ-tubulin (GTU-88), 1:1,000 (Sigma-Aldrich; cat. no. T6557, RRID: AB_477584); goat anti-HRP Cy3-conjugated, 1:250 (Jackson ImmunoResearch Labs; cat. no. 123-165-021, RRID: AB_2338959); goat anti-guinea pig Alexa Fluor 488--conjugated, 1:1,000 (Thermo Fisher Scientific; cat. no. A-11073, RRID: AB_2534117); donkey anti-mouse Alexa Fluor 488­­--conjugated IgG (H + L), 1:1,000 (for GluRIIA stainings; Jackson ImmunoResearch Labs; cat. no. 715-545-150); goat anti-rabbit Alexa Fluor 488--conjugated, 1:1,000 (Thermo Fisher Scientific; cat. no. A-11008, RRID: AB_143165); goat anti-mouse Alexa Fluor 488--conjugated, 1:1,000 (Thermo Fisher Scientific; cat. no. A-21121, RRID: AB_2535764); goat anti-HRP Alexa Fluor 647--conjugated, 1:250 (Jackson ImmunoResearch Labs; cat. no. 123--605-021, RRID: AB_2338967). DNA was stained with DAPI (Thermo Fisher Scientific; cat. no. D3571, RRID: AB 2307445) at 1 µg/ml in PBST (pH 7.3) for 5 min at RT and washed two times for 10 min with PBS.

Stained preparations were imaged in PBS (pH 7.3) at RT with an Olympus microscope BX50WI equipped with a 60× water-immersion objective (LUMPLFL; N.A., 0.9). Images were acquired using a confocal laser scanner (Olympus FluoView300) using a multiargon (630), green HeNe (430), and/or a red HeNe (630) laser and BA 510, BA 530, BA 660, and/or BA 605 filters. Optical sections in the vertical axis were acquired in 1-µm intervals using Fluoview300 software. Acquired images were saved as raw data (TIFF files) in FluoView format. Display images were saved as 8-bit RGB TIFF files. Images were analyzed offline using ImageJ software (FIJI; National Institutes of Health). Fluorescence intensity measurements were performed on nondeconvolved z-stack images or single optical sections. Gamma adjustments were not performed. For publication, figures of images and data were compiled and prepared with Photoshop CC (Adobe). Contrast and intensity of images was minimally adjusted. Images were cropped, if necessary.

For quantification of fluorescence signals, control and mutant larvae were dissected in the same dish such that fixation and antibody incubation were performed identically. All samples were imaged with the same laser settings. Fluorescence intensity per area was determined from a region of interest encompassing single synaptic boutons or GluR clusters by using ImageJ Software. To assess muscle size, muscle length and width were measured using ImageJ. Muscle surface area for muscles 6 and 7 was approximated by calculating the surface area of a cylinder. Bouton number was normalized to muscle surface area. For the analysis of ubiquitinated foci, the total number of distinct and bright FK2-positive puncta at the NMJ (both presynaptic and postsynaptic regions) were counted and normalized to NMJ length. The total number of FK2 puncta in nuclei were assessed by using the automatic nuclei counter ImageJ plug-in, ITCN (Image-based tool for counting nuclei).

Electrophysiology {#s27}
-----------------

Intracellular whole-cell recordings with a single microelectrode filled with 3 M KCl (20--40 MΩ) were made from muscle 6 (abdominal segment A3) of third-instar larvae in HL3 (70 mM NaCl, 5 mM KCl, 10 mM MgCl~2~, 115 mM sucrose, 5 mM trehalose, 10 mM NaHCO~3~, and 5 mM Hepes) supplemented with 0.6 mM Ca^2+^ unless otherwise specified. Recordings examining synaptic homeostasis used HL3 solution containing 4 mM MgCl~2~. mEPPs were continuously recorded for 1 min, and the first 30 events were used to calculate average mEPP amplitudes. To elicit EPPs, the segmental nerve was stimulated through a glass capillary electrode (internal diameter, 10 µm) for 0.3 ms at 2 times the stimulus amplitude required for a threshold response. 15 EPPs were acquired at 0.1 Hz per larvae for analysis. Voltage signals were amplified with an Axoclamp 2B amplifier (Axon Instruments), filtered at 1 kHz, and digitized at 5 kHz directly to disk with a DigiData 1200 interface and pClamp 8.0 software (Axon Instruments). Evoked EPPs were analyzed using ClampFit 10.2 software (Molecular Devices), and spontaneous mEPPs were analyzed using Mini Analysis 6.0.0.7 (Synaptosoft). All experiments were performed at RT (20--22°C).

Data were collected from animals with resting membrane potentials less than −60 mV, and recording data were discarded when the resting membrane potential shifted \>5 mV during the course of an experiment. Only one muscle per larvae was recorded in each individual experiment. For the baseline synaptic transmission data, animals with input resistances \>4 MOhm were used. For neuronal rescue experiments, animals with input resistances \>3 MOhm were used. Quantal content of evoked release was estimated by calculating the ratio of EPP/mEPP amplitudes and correcting for nonlinear summation using a reverse potential of 0 mV ([@bib49]; [@bib5]).

Western blot analysis {#s28}
---------------------

Third-instar larval brains were dissected in HL3, transferred to 2× Laemmli buffer (120 mM Tris HCl, pH 6.8, 4% SDS, 200 mM DTT, and 0.02% bromophenol blue), homogenized, boiled for 3 min, and centrifuged for 1 min. The soluble fraction was recovered, and ∼1 brain equivalent was used for SDS-PAGE run at 80 V (Mini-Protean Cell; BioRad). Separated proteins were blotted onto nitrocellulose membranes at 20 V for 6 min using an iBlot system (Invitrogen). After transfer, the blot was blocked for 30 min using 5% nonfat dry milk or 2% BSA in 0.2% PBS Tween-20, pH 7.3. Blots were incubated with primary antibodies overnight at 4°C and HRP-conjugated secondary antibodies for 2 h at 4°C. To normalize for protein loading, blots were stripped (no. 21059; Thermo Fisher Scientific) for 15 min at RT and immunoblotted for housekeeping proteins. Blots were imaged using a Bio-Rad Western Clarity ECL kit and ChemiDoc XRS imaging system. Protein band intensities were quantified via densitometry analysis with Quantity One software (Bio-Rad). Antibodies were diluted in PBS containing 0.2% Tween-20 as follows: anti-DCAF12, 1:20,000 (GP12); mouse anti-GFP, 1:500 (JL-8; Clontech; cat. no. 632380); mouse anti-V5, 1:1,000 (Thermo Fisher Scientific; cat. no. R960-25, RRID: AB_2556564); goat anti-GAPDH, 1:3,000 (Novus; cat. no. NB300-320, RRID: AB_10001796); mouse anti-β-tubulin, 1:1,000 (DSHB; cat. no. E7, RRID: AB_528499); goat anti-guinea pig HRP-conjugated 1:5,000 (Santa Cruz Biotechnology; cat. no. sc-2438, RRID: AB_650492); goat anti-mouse IgG HRP-conjugated 1:5,000 (Thermo Fisher Scientific; cat. no. 32430, RRID: AB_1185566).

GFP-trap assay {#s29}
--------------

To generate N-terminal--tagged EGFP-DDB1, EGFP was cloned into a pMT/V5-His-C vector using *Xba*I and *Kpn*I restriction sites (pMT/V5-EGFP). DDB1/piccolo cDNA was then PCR amplified using primers containing a *Kpn*I (5′-TA[GGTACC]{.ul}TCGCATCACTACGTGGTGACGG-3′) or *Spe*I site **(**5′-TA[ACTAGT]{.ul}TCAATGCATGCGCGTGAGGTCCTCG-3′). The PCR products were cut with *Kpn*I or *Spe*I and cloned in frame to EGFP of the pMT-EGFP vector. A stop codon after DDB1 precluded expression of downstream sequence including the C-terminal V5 and 6xHis-tags of the original pMT/V5-His-C vector. To generate N-terminal V5-tagged DCAF12, DCAF12 cDNA (DGRC) was PCR amplified using primers containing a *Kpn*I (underlined) followed by a V5 tag (italic, 5′-TA[GGTACC]{.ul}*ATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCT*ACGTTCAACGGGATGGTGAGAACCATCCGC-3′) or a *Not*I (underlined) site (5′-TA[GCGGCCGC]{.ul}CTATTGCCAAACGCCCGCATAGTTGCCC-3′). The PCR product was cut with *Kpn*I and *Not*I and cloned into a pMT/V5-His-C vector. A stop codon after DCAF12 precluded expression of the downstream V5 and 6x His-tags of the original vector.

*Drosophila* S2 cells were transfected with 2 µg total plasmid DNA using Amaxa Nucleofector 2b (Lonza). Expression of EGFP, V5-DCAF12, or EGFP-DDB1 was induced from the metallothionein promoter with 1.5 mM CuSO~4~. After 24 h, proteins were extracted by lysing cells in 0.5 ml of cell lysis buffer (CLB; 50 mM Tris, pH 7.2, 125 mM NaCl, 1 mM EGTA, 1 mM DTT, 0.5% Triton X-100, 0.1 mM PMSF, and 10 µg/ml soy bean trypsin inhibitor). Extracts were clarified by centrifugation and diluted to 2--5 mg/ml in CLB. For GFP pull-downs ([@bib60]), purified GFP-binding protein (GFP-BP) was cross-linked to protein A--coupled Sepharose using dimethylpimelimidate. GFP-BP cross-linked beads were washed three times with 1.5 ml of cell lysis buffer and incubated with the protein extract for 45 min at 4°, washed three times with CLB, and resuspended in Laemmli sample buffer.

DCAF12-Cul4 coimmunoprecipitation {#s30}
---------------------------------

Protein A-G Plus agarose beads (sc-2003; Santa Cruz Biotechnology) were incubated with 4 µg mouse anti-Flag M2 (Sigma-Aldrich) on a rotator for 2 h at 4°C. 0.5 ml of fly heads was homogenized in 1 ml of IP buffer containing 1% Triton X-100, 25 mM Tris-HCl, pH 8.0, 150 mM NaCl, and the Complete Mini protease inhibitor cocktail (Sigma-Aldrich). After homogenization, the cell lysate was cleared of debris by centrifugation at 14,000 rpm for 10 min at 4°C. The cleared supernatant was then incubated with the Flag beads for 2 h on a rotator at 4°C. Agarose beads were spun down with a tabletop centrifuge at 2,000 rpm, and the supernatant was removed and stored. The beads were washed three times for 1 min with 100 μl of IP buffer via repeated resuspension and centrifugation at 2,000 rpm. Beads were resuspended in 2× Laemmli buffer, boiled for 3 min, and centrifuged for 1 min. The supernatant of precipitated proteins was used for SDS-PAGE and Western blot analysis.

Electron microscopy {#s31}
-------------------

Dissected larvae were fixed in Trump's fixative (1% paraformaldehyde, 3% glutaraldehyde, 100 mM cacodylate buffer \[CB\], pH 7.2, 2 mM sucrose, and 0.5 mM EGTA) for 1 to 2 h at RT and then overnight at 4°C. After washing in CB containing 264 mM sucrose (three times for 10 min), the tissue was postfixed with 2% OsO4 in CB for 1 h at RT, dehydrated in a series of ethanol dilutions (50%, 70%, 95%, and 100%) followed by propylene oxide, and embedded in Epon/Araldite. Serial cross sections were poststained with 4% uranyl acetate and lead citrate. Images were obtained on a JEOL 1200EX with an AMT XR80M-B camera running AMT software. For publication, figures were compiled and prepared with Photoshop CC. Contrast and intensity of images was minimally adjusted. Images were cropped, if needed.

Larval locomotion assay {#s32}
-----------------------

Wandering third-instar larvae grown at 23°C were selected, washed gently with distilled water, and transferred with a paintbrush to the center of a 100 × 15-mm grape juice agar plate. Grape juice agar plates were made with Welch's 100% grape juice, distilled water, bacteriological agar, glacial acetic acid, and ethanol (Beverly Clendening, Hofstra University, Hempstead, NY). Larvae were recorded for 3 min, and the total distance traveled by each larva was calculated by scanning individual larval traces, which were manually drawn on the plate lid. Track length was measured with ImageJ software.

Data and statistical analysis {#s33}
-----------------------------

Data from at least three independent animals or experimental trials were used for statistical analysis. Data are represented as means, and error bars represent SEM. Gaussian distributions of data were assessed using a D'Agostino and Pearson omnibus or Shapiro--Wilk normality test. Statistical significance was assessed by either a two-tailed *t* test, Mann--Whitney, or one-way ANOVA (Kruskal--Wallis for nonparametric data) test with appropriate post hoc tests using Prism software (Graphpad Software).

Online supplemental material {#s34}
----------------------------

Fig. S1 shows the subcellular localization of DCAF12 in larval neurons, glia, and muscles. Fig. S2 depicts structural effects and changes in synaptic GluR levels at *dcaf12* mutant NMJs. Fig. S3 shows the electrophysiological properties of transmitter release and Mg^2+^ dependence of evoked release at *dcaf12* mutant NMJs. Fig. S4 shows the subcellular localization of DCAF12 following presynaptic expression of DCAF12 or ΔNLS-DCAF12, the effects of presynaptic and postsynaptic expression of DCAF12 or ΔNLS-DCAF12 on electrophysiological properties of *dcaf12* mutant NMJs, and vGlut expression levels in controls and dcaf12 mutants. Fig. S5 shows effects of DCAF12 mutations on synaptic homeostasis and absolute values of the normalized data shown in [Fig. 9, J--M](#fig9){ref-type="fig"}.
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